Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gogas

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2011
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) StudyA Psyrri, K T Kalogeras, R Kronenwett, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2012
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trialK Pliarchopoulou, K T Kalogeras, R Kronenwett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2022
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF<sup>V600</sup> mutation-positive melanomaC Robert, K D Lewis, R Gutzmer, et al.
British Journal of Cancer|November 6, 2008
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyA K Koutras, K T Kalogeras, M-A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2020
Cobimetinib plus atezolizumab in BRAF<sup>V600</sup> wild-type melanoma: primary results from the randomized phase III IMspire170 studyH Gogas, B Dréno, J Larkin, et al.
Breast Cancer Research and Treatment|May 17, 2008
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group studyG Fountzilas, U Dafni, M A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2006
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyV Malamou-Mitsi, H Gogas, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2005
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, D Skarlos, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, H P Kalofonos, U Dafni, et al.
Cancer Chemotherapy and Pharmacology|September 9, 2011
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trialP Skarlos, C Christodoulou, K T Kalogeras, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2011
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) StudyA Psyrri, K T Kalogeras, R Kronenwett, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2012
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trialK Pliarchopoulou, K T Kalogeras, R Kronenwett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2022
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF<sup>V600</sup> mutation-positive melanomaC Robert, K D Lewis, R Gutzmer, et al.
British Journal of Cancer|November 6, 2008
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyA K Koutras, K T Kalogeras, M-A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2020
Cobimetinib plus atezolizumab in BRAF<sup>V600</sup> wild-type melanoma: primary results from the randomized phase III IMspire170 studyH Gogas, B Dréno, J Larkin, et al.
Breast Cancer Research and Treatment|May 17, 2008
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group studyG Fountzilas, U Dafni, M A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2006
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyV Malamou-Mitsi, H Gogas, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2005
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, D Skarlos, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, H P Kalofonos, U Dafni, et al.
Cancer Chemotherapy and Pharmacology|September 9, 2011
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trialP Skarlos, C Christodoulou, K T Kalogeras, et al.
Pageof 8